STOCK TITAN

Rallybio (RLYB) SEC Filings, Aug 2025-Feb 2026

RLYB NASDAQ

Rallybio Corporation's SEC filings document material events for a clinical-stage biotechnology issuer developing rare-disease therapies in complement dysregulation and hematology. Its 8-K disclosures cover operating and financial results, clinical or regulatory updates, material agreements, and capital-structure matters tied to its common stock.

The filing record also includes stockholder voting results and governance disclosures, including certificate-of-incorporation amendments, reverse stock split disclosure, Nasdaq Capital Market listing matters, and registered common stock information. Agreement filings describe transactions involving Rallybio IPB, LLC, RE Ventures I, LLC, Recursion and the REV102 ENPP1 program, alongside emerging-growth-company reporting status and other material-event disclosures.

Rhea-AI Summary

Rallybio Corp’s major venture backer 5AM Ventures and related entities have updated their ownership positions in the company’s common stock. The amendment shows 5AM Ventures V, L.P. holding 135,319 shares, or 2.6% of Rallybio’s outstanding common stock, and 5AM Opportunities I, L.P. holding 156,469 shares, or 3.0%.

Managing members Andrew J. Schwab and Dr. Kush Parmar each report beneficial ownership of 291,788 shares, representing 5.5% of the common stock, while Dr. Scott M. Rocklage reports 135,319 shares, or 2.6%. These percentages are based on 5,280,471 shares outstanding as of December 30, 2025, after an 8‑for‑1 reverse stock split effective February 2, 2026.

The filing also notes recent open‑market sales by 5AM Ventures V. On February 25, 2025, it sold 87,052 shares at prices between $6.00 and $6.15 per share, with a weighted average of $6.07. On February 26, 2025, it sold 75,000 shares at prices between $6.00 and $6.14, with a weighted average of $6.06.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
45.49%
Tags
ownership
-
Rhea-AI Summary

Rallybio Corp Chief Financial Officer Jonathan I. Lieber reported mixed stock transactions. On February 18, 2026, he acquired 2,500 shares of Rallybio common stock as a grant or award at $0.00 per share. On February 23, 2026, he sold 789 shares of common stock at an average price of $5.06 per share, and a footnote explains this sale was made solely to cover tax withholding obligations from the vesting of a performance stock award. Following these transactions, he directly holds 4,115 shares of Rallybio common stock.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.00%
Tags
insider
-
Rhea-AI Summary

Rallybio Corp director Martin Mackay received a stock option grant tied to his board compensation. The Form 4 shows an award of options to purchase 18,055 shares of common stock at an exercise price of $3.60 per share.

The option was issued under Rallybio’s 2021 Equity Incentive Plan in lieu of $65,000 in retainer fees. It vests in 11 equal installments, each on the last day of the remaining months of calendar year 2026, meaning the award becomes exercisable gradually over that period rather than all at once.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.70%
Tags
insider
Rhea-AI Summary

Rallybio Corp director Ronald Hunt received an option grant to acquire 14,305 shares of common stock at $3.60 per share. The option was issued under the 2021 Equity Incentive Plan in lieu of $51,500 in retainer fees and vests in 11 equal monthly installments over the remaining months of 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.70%
Tags
insider
-
Rhea-AI Summary

Rallybio Corporation received an updated ownership report showing Viking Global’s group holding a significant passive stake. The Viking entities report beneficial ownership of 4,222,969 shares of Rallybio common stock, equal to 9.99% of the class, including shares underlying pre-funded warrants.

The warrants allow purchase of 3,333,388 shares at an exercise price of $0.0001 per share, but a 9.99% “Blocker” limits how many can be exercised at any time, with 28,192 warrant shares currently counted in beneficial ownership. Viking certifies the securities are not held for the purpose of changing or influencing control of Rallybio.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.77%
Tags
ownership
-
Rhea-AI Summary

Rallybio Corporation approved and scheduled a 1-for-8 reverse stock split of its common stock. The split will become effective at 12:01 a.m. Eastern Time on February 6, 2026, after which the stock will trade on a post-split basis under a new CUSIP.

Stockholders approved the amendment at a special meeting, with 34,507,021 votes in favor, 464,514 against, and 11,939 abstentions. As of the December 30, 2025 record date, 42,243,774 shares were outstanding and entitled to vote, and 34,983,474 shares were represented, constituting a quorum.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.86%
Tags
current report
Rhea-AI Summary

Rallybio (RLYB) filed its Q3 2025 10‑Q reporting a swing to profitability driven by a joint‑venture sale. The company recorded net income of $16.0 million for the quarter, reflecting $22.5 million of total other income including a $22.4 million gain on the sale of its REV102 JV interest. Core operations remained loss‑making with loss from operations of $6.9 million as R&D fell to $4.1 million and G&A to $3.0 million. Revenue from collaboration and license activities was $212 thousand.

Cash, cash equivalents and marketable securities were $59.3 million as of September 30, 2025. Management states these resources are expected to fund operations for more than 12 months, and elsewhere indicates funding sufficiency through 2027. Weighted‑average shares outstanding were 45,058,591 for the quarter; shares outstanding were 42,243,774 as of October 31, 2025.

The lead asset RLYB116 advanced with a confirmatory PK/PD multiple‑dose study underway; top‑line data are anticipated in Q4 2025. The company discontinued the RLYB212 program in April 2025 and completed a workforce reduction in May 2025 to focus resources on RLYB116 and preclinical programs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.18%
Tags
quarterly report
-
Rhea-AI Summary

Rallybio Corporation (RLYB) furnished an 8-K stating it issued a press release announcing financial results for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1.

The company noted that the information in Item 2.02, including Exhibit 99.1, is furnished and not deemed “filed” under the Exchange Act, which limits potential liability and incorporation by reference unless specifically stated.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.18%
Tags
current report
-
Rhea-AI Summary

Rallybio Corporation received an additional grace period from Nasdaq to fix a share price problem that threatens its stock market listing. After its common stock traded below the required $1.00 minimum closing bid price for 30 straight business days and failed to recover by the initial August 25, 2025 deadline, Nasdaq approved the company’s transfer from the Nasdaq Global Select Market to the Nasdaq Capital Market.

The transfer took effect at the opening of business on August 29, 2025, and the stock continues to trade under the symbol “RLYB”. Rallybio now has until February 23, 2026 to regain compliance with Nasdaq’s bid price rule. The company plans to monitor its share price and is considering options to restore compliance, including a potential reverse stock split if needed.

If Rallybio does not meet the minimum bid price requirement by the new deadline, Nasdaq may move to delist the stock, although the company would have the right to appeal that decision to a Nasdaq Hearings Panel.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.91%
Tags
current report
Form 10-Q
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.15%
Tags
quarterly report

FAQ

How many Rallybio (RLYB) SEC filings are available on StockTitan?

StockTitan tracks 83 SEC filings for Rallybio (RLYB), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Rallybio (RLYB)?

The most recent SEC filing for Rallybio (RLYB) was filed on November 12, 2026.